The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
SWOG S1929: Phase II randomized study of maintenance atezolizumab (A) versus atezolizumab + talazoparib (AT) in patients with SLFN11 positive extensive stage small cell lung cancer (ES-SCLC).
 
Nagla Fawzy Abdel Karim
Stock and Other Ownership Interests - Abbott Biotherapeutics (I)
Consulting or Advisory Role - Amgen; Bayer; Bristol Myers Squibb Foundation; G1 Therapeutics; Jazz Pharmaceuticals; Sanofi/Regeneron
Speakers' Bureau - AstraZeneca; Sanofi/Regeneron
Research Funding - Bristol-Myers Squibb/Pfizer (Inst); Exelixis (Inst); Genentech (Inst); Pfizer (Inst)
 
Jieling Miao
No Relationships to Disclose
 
Karen L. Reckamp
Consulting or Advisory Role - Amgen; AstraZeneca; Blueprint Medicines; Daiichi Sankyo/Lilly; EMD Serono; Genentech; GlaxoSmithKline; Janssen Oncology; Lilly; Merck KGaA; Mirati Therapeutics; Seagen; Takeda
Research Funding - Blueprint Medicines; Calithera Biosciences (Inst); Daiichi Sankyo/Astra Zeneca (Inst); Elevation Oncology (Inst); Genentech/Roche (Inst); Janssen Oncology (Inst)
 
Carl Michael Gay
Honoraria - Aptitude Health; OncLive/MJH Life Sciences; Peerview
Consulting or Advisory Role - AstraZeneca/MedImmune; Bristol-Myers Squibb; G1 Therapeutics; Jazz Pharmaceuticals; KisoJi Biotechnology; Monte Rosa Therapeutics; Pharmerit
Speakers' Bureau - AstraZeneca; BeiGene
Research Funding - AstraZeneca
Patents, Royalties, Other Intellectual Property - Patent pending related to small cell lung cancer transcriptional subtypes.
Travel, Accommodations, Expenses - Dava Oncology; ESMO
 
Lauren Averett Byers
Honoraria - Clinical Care Options; UpToDate
Consulting or Advisory Role - Abbvie; Amgen; Arrowhead Pharmaceuticals; AstraZeneca; BeiGene; Chugai Pharma; Daiichi Sankyo; Genentech; Jazz Pharmaceuticals; Merck Sharp & Dohme Corp.; Puma Biotechnology
Research Funding - Amgen (Inst); AstraZeneca (Inst); Jazz Pharmaceuticals (Inst)
 
Yingqi Zhao
No Relationships to Disclose
 
Mary Weber Redman
No Relationships to Disclose
 
Daniel R. Carrizosa
Consulting or Advisory Role - Curio Science; Sanofi; Sanofi/Regeneron
Speakers' Bureau - PER
Research Funding - AstraZeneca (Inst); Elevation Oncology (Inst); GlaxoSmithKline (Inst); Ignyta (Inst); Merck (Inst); Takeda (Inst)
 
Wei-Lien Wang
No Relationships to Disclose
 
William J. Petty
Consulting or Advisory Role - Jazz Pharmaceuticals; Mirati Therapeutics
Research Funding - Abbvie (Inst); Merck Sharp & Dohme (Inst)
Travel, Accommodations, Expenses - Dava Oncology
 
Kathan Mehta
No Relationships to Disclose
 
Bryan A. Faller
Consulting or Advisory Role - LEK
Travel, Accommodations, Expenses - Amgen; AstraZeneca; Boehringer Ingelheim; Celgene; EB SQUIBB; Eisai; Genentech; Lilly; Merck; Novartis; Takeda
 
Edem S. Agamah
No Relationships to Disclose
 
Samer S. Kasbari
No Relationships to Disclose
 
Rajini Katipamula Malisetti
No Relationships to Disclose
 
Atul Kumar
No Relationships to Disclose
 
John Schallenkamp
No Relationships to Disclose
 
Krishna Chaitanya Alluri
Stock and Other Ownership Interests - Abbvie
 
Jhanelle Elaine Gray
Honoraria - Jazz Pharmaceuticals; Merck; OncoCyte
Consulting or Advisory Role - AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca/MedImmune; Blueprint Medicines; Blueprint Medicines; Blueprint Medicines; Bristol Myers Squibb; EMD Serono; Janssen Scientific Affairs; Jazz Pharmaceuticals; Lilly; Loxo; Merck Sharp & Dohme; National Comprehensive Cancer Network; Novartis; Sanofi
Research Funding - Array BioPharma (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); ECOG-ACRIN (Inst); G1 Therapeutics (Inst); Genentech/Roche (Inst); Ludwig Institute for Cancer Research (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); SWOG (Inst)
Travel, Accommodations, Expenses - Novartis; OncoCyte
 
Karen Kelly
Consulting or Advisory Role - Abbvie; Amgen; AstraZeneca; Daiichi Sanko; Debiopharm Group; Eisai; EMD Serono; Genentech; Genmab; Janssen; Lilly; Novartis; Regeneron; Sanofi; Takeda; Targeted Oncology
Research Funding - Abbvie (Inst); Amgen (Inst); Astellas Pharma (Inst); Bristol-Meyers Squibb (Inst); EMD Serono (Inst); Five Prime Therapeutics (Inst); Genentech (Inst); Jounce Therapeutics (Inst); Lilly (Inst); Novartis (Inst); Regeneron (Inst); Tizona Therapeutics, Inc. (Inst)
Patents, Royalties, Other Intellectual Property - Author Royalties for UpToDate, an evidence based, peer reviewed information resource, available via the web, desktop, and PDA.